Balyasny Asset Management
AVIR icon

Balyasny Asset Management’s Atea Pharmaceuticals AVIR Stock Holding History

Balyasny Asset Management’s Portfolio AVIR Stock Details AVIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-44,346
Closed -$213K – 2638
2022
Q4 		$213K Sell
44,346
-706,727
-94% -$3.58M ﹤0.01% 2114
2022
Q3 		$4.27M Sell
751,073
-1,048,434
-58% -$8.03M 0.01% 1081
2022
Q2 		$12.8M Buy
1,799,507
+1,788,546
+16,317% +$12.2M 0.04% 569
2022
Q1 		$79K Sell
10,961
-243,657
-96% -$1.65M ﹤0.01% 2175
2021
Q4 		$2.28M Buy
+254,618
New +$3.97M 0.01% 1165
2021
Q3 		– Sell
-399,227
Closed -$8.57M – 1932
2021
Q2 		$8.57M Buy
+399,227
New +$12M 0.04% 553

Other funds holding AVIR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Balyasny Asset Management's AVIR Position: Q1 2023 in Review

Balyasny Asset Management sold out of Atea Pharmaceuticals (AVIR) in Q1 2023, closing a stake of 44,346 shares — an estimated $213K sold.

Balyasny Asset Management first reported a position in AVIR in Q2 2021 and held it in 6 quarters. The position peaked at $12.8M in Q2 2022. 130 funds tracked by Wall St. Rank hold AVIR as of Q1 2023.

  • Balyasny Asset Management reported no remaining Atea Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
  • Balyasny Asset Management sold 44,346 Atea Pharmaceuticals shares in Q1 2023, an estimated $213K.
  • Balyasny Asset Management first reported a position in Atea Pharmaceuticals in Q2 2021 and held it in 6 quarters.
  • Balyasny Asset Management's Atea Pharmaceuticals position peaked at $12.8M in Q2 2022.
  • 130 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q1 2023.

Based on Balyasny Asset Management's 13F filing for Q1 2023, filed 15 May 2023.